Robert A Seder

And so maybe just a quick sort of side note here is that the other part of our work recently has been to conduct clinical trials of anti-malaria monoclonal antibodies in Africa.

And this is work with a close friend and collaborator, Bob Seder at the Vaccine Research Center at the NIH, who isolated some very potent monoclonal antibodies that target a protein on this first stage.

of the infection.

And we find in clinical trials that a single dose of antibodies against sporozoites can protect for up to six months against infection, like completely blocking the infection at the first stage.